Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) have been assigned a consensus rating of “Moderate Buy” from the nineteen research firms that are currently covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $45.53.

Several analysts recently weighed in on APLS shares. Wedbush lowered their price objective on Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Monday. Royal Bank of Canada lowered their price objective on Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating for the company in a report on Monday. JPMorgan Chase & Co. upped their target price on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a report on Tuesday. Wells Fargo & Company lowered their target price on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating for the company in a report on Wednesday, November 6th. Finally, Oppenheimer lowered their target price on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th.

Insider Buying and Selling

In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 2,824 shares of the business’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $29.52, for a total transaction of $83,364.48. Following the sale, the chief executive officer now directly owns 415,695 shares of the company’s stock, valued at $12,271,316.40. The trade was a 0.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO James George Chopas sold 1,096 shares of the business’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total transaction of $33,351.28. Following the sale, the chief accounting officer now directly owns 48,138 shares in the company, valued at approximately $1,464,839.34. This trade represents a 2.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 60,365 shares of company stock valued at $1,810,479 in the last three months. 6.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Apellis Pharmaceuticals

Several large investors have recently added to or reduced their stakes in APLS. EverSource Wealth Advisors LLC increased its stake in shares of Apellis Pharmaceuticals by 2,707.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock worth $25,000 after acquiring an additional 758 shares during the last quarter. Wolverine Asset Management LLC acquired a new position in shares of Apellis Pharmaceuticals in the third quarter worth $27,000. True Wealth Design LLC acquired a new position in shares of Apellis Pharmaceuticals in the third quarter worth $27,000. Signaturefd LLC increased its stake in shares of Apellis Pharmaceuticals by 357.2% in the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock worth $37,000 after acquiring an additional 918 shares during the last quarter. Finally, Capital Performance Advisors LLP acquired a new position in shares of Apellis Pharmaceuticals in the third quarter worth $56,000. 96.29% of the stock is owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Stock Up 3.8 %

Shares of Apellis Pharmaceuticals stock opened at $26.00 on Thursday. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The firm has a market cap of $3.23 billion, a P/E ratio of -12.81 and a beta of 0.93. Apellis Pharmaceuticals has a fifty-two week low of $23.77 and a fifty-two week high of $64.33. The business has a 50-day moving average price of $29.53 and a 200 day moving average price of $31.30.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.08. The firm had revenue of $212.50 million during the quarter, compared to analyst estimates of $197.92 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. Apellis Pharmaceuticals’s quarterly revenue was up 45.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.73) earnings per share. On average, sell-side analysts forecast that Apellis Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).